| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
Welireg is owned by Merck Sharp Dohme.
Welireg contains Belzutifan.
Welireg has a total of 2 drug patents out of which 0 drug patents have expired.
Welireg was authorised for market use on 13 August, 2021.
Welireg is available in tablet;oral dosage forms.
Welireg can be used as treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor.
Drug patent challenges can be filed against Welireg from 13 August, 2025.
The generics of Welireg are possible to be released after 05 September, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Dosage: TABLET;ORAL
WELIREG family patents
